Cogent Biosciences, Inc. Profile Avatar - Palmy Investing

Cogent Biosciences, Inc.

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation t…

Biotechnology
US, Cambridge [HQ]

Document Reader

Click To Read:

DEF 14-A Proxies

Not a single DEF 14-A proxy doc.

10-K Filings

Not a single 10-K doc.

10-Q Filings

Not a single 10-Q doc.

LDA 1/2 Filings [Lobbying]

Not a single LDA doc.

End of COGT's Analysis
CIK: 1622229 CUSIP: 19240Q201 ISIN: US19240Q2012 LEI: - UEI: -
Secondary Listings
COGT has no secondary listings inside our databases.